Keyword Analysis & Research: tolvaptan mechanism of action
Keyword Research: People who searched tolvaptan mechanism of action also searched
Search Results related to tolvaptan mechanism of action on Search Engine
-
Tolvaptan: Uses, Interactions, Mechanism of Action | DrugBank …
https://go.drugbank.com/drugs/DB06212
WEBMechanism of action. Tolvaptan is a selective and competitive arginine vasopressin receptor 2 antagonist. Vasopressin acts on the V2 receptors found in the walls of the vasculature and luminal membranes of renal collecting ducts.
DA: 62 PA: 29 MOZ Rank: 84
-
Tolvaptan - PMC - National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248250/
WEBMechanism. Symptomatic hyponatremia can accompany heart failure, SIADH and liver cirrhosis. Increased concentrations of vasopressin (also known as antidiuretic hormone, ADH) contribute via overstimulation of vasopressin-2 (V2) receptors in renal collecting ducts ( Figure 1A ).
DA: 96 PA: 15 MOZ Rank: 61
-
Tolvaptan: Dosage, Mechanism/Onset of Action, Half-Life
https://www.medicine.com/drug/tolvaptan/hcp
WEBFeb 10, 2020 · Mechanism of Action An arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V 2 and V 1a in a ratio of 29:1. Antagonism of the V 2 receptor by tolvaptan promotes the excretion of free water (without loss of serum electrolytes) resulting in net fluid loss, increased urine output, decreased urine …
DA: 17 PA: 16 MOZ Rank: 71
-
Tolvaptan - Wikipedia
https://en.wikipedia.org/wiki/Tolvaptan
WEBTolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V 2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).
DA: 91 PA: 43 MOZ Rank: 38
-
Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, …
https://www.nejm.org/doi/full/10.1056/NEJMoa065181
WEBNov 16, 2006 · Tolvaptan, a novel, orally active, selective, nonpeptide antagonist that blocks arginine vasopressin from binding to V 2 receptors of the distal nephron, induces...
DA: 68 PA: 84 MOZ Rank: 32
-
Tolvaptan - PMC - National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134612/
WEBTolvaptan: Mechanism of Action. Tolvaptan binds to V2 receptor with 1.8 times greater affinity than ADH. The drug is a selective V2 receptor antagonist and shows 30 times more avidity for V2 receptor than V1 receptors.
DA: 52 PA: 92 MOZ Rank: 60
-
Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470182/
WEBNov 12, 2014 · Tolvaptan is an arginine vasopressin (AVP) antagonist that acts to increase excretion of free water (aquaresis) in patients without introducing electrolyte abnormalities or worsening renal function. It works via blockade of vasopressin-2 receptors at the renal collecting duct.
DA: 41 PA: 2 MOZ Rank: 53
-
DailyMed - TOLVAPTAN- tolvaptan tablet
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f4c5679-8490-45ec-bd34-1a569e3af850
WEBSep 5, 2022 · Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and ... 2 DOSAGE AND ADMINISTRATION.
DA: 40 PA: 69 MOZ Rank: 66
-
Tolvaptan - Dubois - 2012 - British Journal of Clinical ... - Wiley
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2011.04029.x
WEBMay 27, 2011 · Mechanism. Symptomatic hyponatremia can accompany heart failure, SIADH and liver cirrhosis. Increased concentrations of vasopressin (also known as antidiuretic hormone, ADH) contribute via overstimulation of vasopressin-2 (V2) receptors in renal collecting ducts ( Figure 1A ).
DA: 2 PA: 66 MOZ Rank: 23
-
Tolvaptan - an overview | ScienceDirect Topics
https://www.sciencedirect.com/topics/neuroscience/tolvaptan
WEBTolvaptan is a vasopressin type 2 receptor antagonist prescribed to correct hyponatremia or for the treatment of autosomal dominant polycystic kidney disease. The agent carries a Boxed Warning in the United States because rapid correction of hyponatremia may lead to central pontine demyelination.
DA: 97 PA: 53 MOZ Rank: 41
